Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations.

Turk DC, O'Connor AB, Dworkin RH, Chaudhry A, Katz NP, Adams EH, Brownstein JS, Comer SD, Dart R, Dasgupta N, Denisco RA, Klein M, Leiderman DB, Lubran R, Rappaport BA, Zacny JP, Ahdieh H, Burke LB, Cowan P, Jacobs P, Malamut R, Markman J, Michna E, Palmer P, Peirce-Sandner S, Potter JS, Raja SN, Rauschkolb C, Roland CL, Webster LR, Weiss RD, Wolf K.

Pain. 2012 Oct;153(10):1997-2008. doi: 10.1016/j.pain.2012.05.029. Epub 2012 Jul 5. Review.

2.

Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?

Bannwarth B.

Drugs. 2012 Sep 10;72(13):1713-23. doi: 10.2165/11635860-000000000-00000. Review.

PMID:
22931520
3.

Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain.

Brushwood DB, Rich BA, Coleman JJ, Bolen J, Wong W.

J Pain Palliat Care Pharmacother. 2010 Dec;24(4):333-48. doi: 10.3109/15360288.2010.524979. Review.

PMID:
21133741
4.

Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.

Webster LR, Markman J, Cone EJ, Niebler G.

Postgrad Med. 2017 Jan;129(1):102-110. doi: 10.1080/00325481.2017.1268902. Epub 2016 Dec 12. Review.

PMID:
27915497
5.

Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.

Hale ME, Moe D, Bond M, Gasior M, Malamut R.

Pain Manag. 2016 Oct;6(5):497-508. doi: 10.2217/pmt-2015-0005. Epub 2016 Apr 6. Review.

6.

Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse- deterrent formulations.

Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R.

Curr Pharm Des. 2012;18(37):6109-15. Review.

PMID:
22747546
7.

An overview of prodrug technology and its application for developing abuse-deterrent opioids.

Gudin JA, Nalamachu SR.

Postgrad Med. 2016 Jan;128(1):97-105. doi: 10.1080/00325481.2016.1126186. Epub 2015 Dec 18. Review.

PMID:
26615852
8.

Use of prescription opioids with abuse-deterrent technology to address opioid abuse.

Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.

Curr Med Res Opin. 2014 Aug;30(8):1589-98. doi: 10.1185/03007995.2014.915803. Epub 2014 Apr 24.

PMID:
24738694
9.

Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.

Gasior M, Bond M, Malamut R.

Postgrad Med. 2016 Jan;128(1):85-96. doi: 10.1080/00325481.2016.1120642. Epub 2015 Dec 18. Review.

PMID:
26566680
10.

Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure.

Roland CL, Setnik B, Brown DA.

Postgrad Med. 2017 Jan;129(1):12-21. doi: 10.1080/00325481.2017.1272397. Epub 2016 Dec 25.

PMID:
27960575
11.

Opioid abuse-deterrent strategies: role of clinicians in acute pain management.

Webster LR, Brennan MJ, Kwong LM, Levandowski R, Gudin JA.

Postgrad Med. 2016 Jan;128(1):76-84. doi: 10.1080/00325481.2016.1113841. Epub 2015 Dec 3. Review.

PMID:
26631936
12.

Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.

Cicero TJ, Ellis MS.

JAMA Psychiatry. 2015 May;72(5):424-30. doi: 10.1001/jamapsychiatry.2014.3043.

PMID:
25760692
13.

Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.

Schaeffer T.

J Med Toxicol. 2012 Dec;8(4):400-7. doi: 10.1007/s13181-012-0270-y. Review.

14.

Challenges in the development of prescription opioid abuse-deterrent formulations.

Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD, Passik SD, Schnoll SH, Sellers E, Travers D, Weiss R.

Clin J Pain. 2007 Oct;23(8):648-60. Review.

PMID:
17885342
15.

Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?

Schneider JP, Matthews M, Jamison RN.

CNS Drugs. 2010 Oct;24(10):805-10. doi: 10.2165/11584260-000000000-00000. Review.

PMID:
20839893
16.

Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.

Webster L.

Pain Med. 2009 Jul;10 Suppl 2:S124-33. doi: 10.1111/j.1526-4637.2009.00672.x. Review.

PMID:
19691683
17.

Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain.

Webster L, St Marie B, McCarberg B, Passik SD, Panchal SJ, Voth E.

J Opioid Manag. 2011 May-Jun;7(3):235-45. Review.

PMID:
21823554
18.

American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.

Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S 2nd, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW; American Society of Interventional Pain Physicians.

Pain Physician. 2012 Jul;15(3 Suppl):S67-116.

19.

Establishing "abuse-deterrence equivalence" for generic abuse-deterrent opioid formulations: A proposed development framework.

Setnik B, Cone EJ.

J Opioid Manag. 2016 May-Jun;12(2):96-100. doi: 10.5055/jom.2016.0320.

PMID:
27194193
20.

The role of abuse-deterrent formulations in countering opioid misuse and abuse.

Nguyen V, Raffa RB, Taylor R, Pergolizzi JV Jr.

J Clin Pharm Ther. 2015 Dec;40(6):629-34. doi: 10.1111/jcpt.12337. Epub 2015 Nov 23. Review.

PMID:
26595258

Supplemental Content

Support Center